Aubagio

April 29, 2019April 29, 2019

Relapsing MS Patients Highly Satisfied with Aubagio’s Efficacy and Ease of Use, Global Clinical Study Finds

Aubagio, News

High levels of satisfaction with the efficacy and convenience of Aubagio (teriflunomide), an oral treatment for relapsing multiple sclerosis (MS), were reported by patients across the U.S. and 13 other countries, ... Read more

April 25, 2019May 23, 2019

Aubagio Lowers Relapse Rate in RRMS Patients, Real-world Observational Study Shows

Aubagio, News

In clinical practice, relapse events dropped by roughly half over a four-year period in relapsing-remitting multiple sclerosis (RRMS) patients treated with Aubagio (teriflunomide), a real-world study reports. The study, “Real-life outcomes of ... Read more

March 11, 2019March 11, 2019

Immunic Therapeutics Enrolls First Patient in Phase 2 Trial of IMU-838 for RRMS

Aubagio, News

Immunic Therapeutics has enrolled the first patient in its Phase 2 clinical trial testing IMU-838, a potential oral therapy for relapsing-remitting multiple sclerosis (RRMS). IMU-838 (vidofludimus calcium) is a next-generation selective ... Read more

March 5, 2019March 11, 2019

Two Different Approaches to Providing Online MS Help

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

I received an email recently from the National Multiple Sclerosis Society in the U.S. promoting a searchable database of “credible doctors and resources.” A few days later, I happened ... Read more

March 5, 2019March 11, 2019

#ACTRIMS2019 – TG Therapeutics’ Investigational Therapy Ublituximab Posts Positive Data in MS Phase 2 Clinical Trial

Aubagio, News

Full results of a Phase 2 clinical trial testing TG Therapeutics’ lead candidate ublituximab (TG-1101) for relapsing multiple sclerosis (MS) showed that treatment for 48 weeks resulted in a marked reduction ... Read more

February 26, 2019March 20, 2019

Switching from Tysabri to Aubagio Can Help Lower Relapse Risk in MS Patients, Phase 4 Trial Shows

Aubagio, News

Stable patients with multiple sclerosis (MS) who transition from Tysabri (natalizumab) treatment to Aubagio (teriflunomide) have a lower relapse risk, a new study shows. The study, “Reducing return of disease ... Read more

February 25, 2019March 20, 2019

MS News that Caught My Eye Last Week: Early DMT Use, Aubagio vs. Tecfidera, Lipoic Acid Study, MS Forums

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

Early Use of High-efficacy DMTs of Long-term Benefit to MS Patients, Real-world Study Reports The question of whether to start treating multiple sclerosis (MS) with an older, less effective ... Read more

February 22, 2019March 20, 2019

Aubagio, Tecfidera Show Comparable Effectiveness in Relapsing MS, Real-world Phase 4 Trial Finds

Aubagio, News

Aubagio (teriflunomide) seems to be superior to Tecfidera (dimethyl fumarate) in slowing whole brain shrinkage in patients with relapsing multiple sclerosis (MS), a new Phase 4 clinical trial shows. However, Aubagio and Tecfidera ... Read more

February 20, 2019March 11, 2019

Early Use of High-efficacy DMTs of Long-term Benefit to MS Patients, Real-world Study Reports

Aubagio, News

Multiple sclerosis (MS) patients given intensive disease-modifying therapies early in their disease course have more favorable long-term outcomes than those treated with an escalating regimen, real-world data shows. The ... Read more

February 15, 2019March 11, 2019

4 Things I’ve Learned About Paying for MS Medications

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

Are you having trouble paying for MS medications? If so, you’re not alone. People change or lose their insurance, and plans change the medications they cover from year to ... Read more

February 8, 2019March 11, 2019

DMT Approvals for Medicare Users Decline While Costs Rise, Study Shows

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

This probably won’t come as a surprise to you if you’re on Medicare: It’s getting harder to obtain approval for many of the disease-modifying therapies (DMTs) prescribed for people ... Read more

February 8, 2019March 11, 2019

Medicare Rules, Higher Cost-sharing Load Increase Out-of-pocket Spending for MS Therapies, Study Reports

Aubagio, News

Restrictive access policies by Medicare and a rising cost-sharing burden lead to an increased price of disease-modifying therapies for multiple sclerosis patients, according to new research. The findings also revealed ... Read more

February 1, 2019July 23, 2019

Why Aren’t You Using an MS Medication?

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

  I see a lot of answers to the question about why people stop, or refuse to start, an MS medication. “Thinking of stopping the…meds. Sick of the shots ... Read more

January 30, 2019March 11, 2019

Canadian RRMS Patients Less Likely to Discontinue Treatment with Oral Gilenya, Compared to Injectable or Infusible Therapies

Aubagio, News

Multiple sclerosis (MS) patients in Canada are more likely to comply with their treatment plan and less likely to discontinue the use of the oral disease-modifying treatment Gilenya (fingolimod), compared ... Read more

January 29, 2019March 20, 2019

Gilenya Better at Lowering Relapse Rate than Tecfidera or Aubagio, Study Suggests

Aubagio, News

Gilenya is linked to significantly lower annualized relapse rates in relapsing-remitting multiple sclerosis (RRMS) patients compared to Tecfidera or Aubagio, a study suggests. All three therapies showed similar effects on disability ... Read more

January 23, 2019March 11, 2019

Favorable Efficacy and Similar Safety with Ocrevus in Relapsing MS, Study Finds

Aubagio, News

Treatment with Ocrevus (ocrelizumab) has superior or comparable effectiveness and a similar safety profile to other available disease-modifying treatments (DMTs) for treating relapsing multiple sclerosis (MS), according to a ... Read more

January 17, 2019March 11, 2019

Fewer RRMS Patients Relapse, Discontinue Treatment with Gilenya, Study Finds

Aubagio, News

Relapsing-remitting multiple sclerosis (RRMS) patients on Gilenya (fingolimod) have fewer relapses and stay on treatment longer than those taking Tecfidera (dimethyl fumarate) or Aubagio (teriflunomide), according to a new study. ... Read more

January 15, 2019March 11, 2019

UK Experts Propose New Guidelines to Treat Women with MS Before, During, After Pregnancy

Aubagio, News

Multiple sclerosis (MS) experts in the United Kingdom have proposed consensus guidelines for the management and treatment of pregnant women with the disease, and couples affected by MS who ... Read more

December 21, 2018March 11, 2019

Shots, Infusions, or Pills for Your MS?

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

  There are more than a dozen disease-modifying therapies available to treat MS. Some are shots, some are infusions, and some are pills. Some are more effective than others. ... Read more

December 7, 2018March 20, 2019

Aubagio Becomes 1st Once-daily Oral DMT for Relapsing MS Patients in India

Aubagio, News

Aubagio (teriflunomide) has become the first once-a-day, oral disease-modifying therapy (DMT) for multiple sclerosis (MS) to be approved for use in India. Sanofi Genzyme’s therapy is indicated for first-line treatment of ... Read more

November 20, 2018March 20, 2019

FDA Approves Generic Version of Aubagio to Treat Relapsing MS, Glenmark Pharma Says

Aubagio, News

The U.S. Food and Drug Administration (FDA) has approved a generic version of  Aubagio (teriflunomide) tablets at the 7 mg and 14 mg  doses marketed by Sanofi, according to the ... Read more

October 16, 2018March 20, 2019

#ECTRIMS2018 – Two European Studies Compare Tecfidera, Aubagio Effectiveness

Aubagio, News

Treatment of relapsing-remitting multiple sclerosis (RRMS) patients with Tecfidera (dimethyl fumarate) is associated with fewer new brain lesions at two years, lower relapse rates, increased time to first relapse, and ... Read more

October 15, 2018March 11, 2019

#ECTRIMS2018 – Plasma Neurofilament Light Levels Linked to Treatment Effects in RRMS, Study Finds

Aubagio, News

Levels of proposed biomarker neurofilament light chain (NfL) are associated with therapeutic effects of disease-modifying treatments (DMTs) in relapsing-remitting multiple sclerosis (RRMS) patients, according to a real-world study. Study findings also ... Read more

October 10, 2018March 11, 2019

#ECTRIMS2018 – Switching to Tysabri Leads to Fewer Relapses and Disability than Gilenya, Study in RRMS Patients Finds

Aubagio, News

Patients with relapsing-remitting multiple sclerosis (RRMS) who switch to Tysabri (natalizumab) after relapses on first-line treatment with other medications show greater relapse reduction and less disability progression than those ... Read more

October 5, 2018March 11, 2019

Could Government Probe Threaten Pharma Patient Assistance Programs?

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

Many of us have received help to pay for our MS medications. Now there’s a chance that assistance could be threatened. A recent article in the The Wall Street ... Read more

September 28, 2018March 11, 2019

#ECTRIMS2018 – Ublituximab Markedly Reduces Lesions, Promotes B-cell Depletion, Halts Disability Progression in Phase 2 Trial

Aubagio, News

A 48-week treatment of relapsing multiple sclerosis (MS) with TG Therapeutics’ investigational compound ublituximab led to a marked reduction of brain and spinal cord lesions, massive depletion of relapse-associated ... Read more

August 24, 2018March 11, 2019

Your MS Med’s Copay Could Be More Expensive than Paying Cash

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

I get my medications the old-fashioned way. When I need to fill a prescription, I either go to the drug store or use a mail-order pharmacy — and usually, ... Read more

August 13, 2018March 11, 2019

MS News That Caught My Eye Last Week: MMJ Chewing Gum, Hair Loss, Botox for Bladder Problems, MS Progression Prediction

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

Hair Loss Seen in RRMS Patients Using Aubagio Often Temporary and Mild, Study Says I read a lot of questions on multiple sclerosis (MS) social media groups from people ... Read more

August 10, 2018March 20, 2019

Hair Loss Seen in RRMS Patients Using Aubagio Often Temporary and Mild, Study Says

Aubagio, News

Hair thinning in relapsing-remitting multiple sclerosis (RRMS) patients using Aubagio is usually mild and temporary, and does not require stopping treatment, a small real-world study reports. The research, “Real-World Observational Evaluation ... Read more

August 10, 2018March 11, 2019

TG Therapeutics Reaches Target Enrollment in Phase 3 Trials to Test Ublituximab in Relapsing MS

Aubagio, News

TG Therapeutics announced it has reached target enrollment in the ULTIMATE I and II Phase 3 clinical trials assessing the use of ublituximab (TG-1101) to treat relapsing forms of ... Read more

July 27, 2018March 11, 2019

Oral DMTs Still Common 1st Therapy for New MS Patients but Ocrevus Having Impact, Market Report Says

Aubagio, News

Oral disease-modifying therapies (DMTs) are the most common first choice of treatment for people newly diagnosed with multiple sclerosis (MS) in the United States, an analysis reports. Antibody-based DMTs ... Read more

June 22, 2018March 11, 2019

#EAN2018 – Mavenclad Greatly Reduces Risk of RRMS Relapse, Analysis Finds

Aubagio, News

New retrospective analysis of the Phase 3 CLARITY study (NCT00213135) shows that treatment with Mavenclad (cladribine tablets) improved annualized relapse rate and magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting ... Read more

June 5, 2018March 11, 2019

#CMSC2018 – New Phase 2 Data Supports Ublituximab in Effectively Lowering Relapses, Depleting B-cells in MS Patients

Aubagio, News

New results from a Phase 2 trial evaluating TG Therapeutics’ ublituximab continue to support the therapy’s efficacy in treating relapsing forms of multiple sclerosis (MS). This investigative infusion therapy ... Read more

May 22, 2018March 11, 2019

I Have MS and I’m Very Lucky

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

National Nurses Week was earlier this month. I’m a little late saying it, but, “Thank you, nurses.” And doctors. I’m really a lucky guy. Lucky to have had fabulous ... Read more

May 9, 2018March 11, 2019

The Agony of Decision-making when It’s Time to Switch MS Medications

Aubagio, Columns, Making a Difference - a Column by Cathy Chester.

I’m agonizing over an important decision and it’s driving me crazy. I’m usually a quick decision-maker, but this one is tough. I have my analytical hat on, trying to ... Read more

April 17, 2018March 11, 2019

I Hope My MS Treatments Are Done for Good

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

With apologies to Edgar Allan Poe, quoth the Lemmie, “Nevermore.” As I write this, the final brown bag of Lemtrada (alemtuzumab) has just begun to drip into a vein ... Read more

April 5, 2018March 11, 2019

MS Path 2 Care Program Aims to Empower Patients to Be Active in Healthcare Journey

Aubagio, Lemtrada, News, Ocrevus

In the first year after being diagnosed with multiple sclerosis (MS) in 1997, Ann Borsellino basically withdrew from life, rarely even leaving her bedroom. Knowing little about the disease, she ... Read more

March 23, 2018March 11, 2019

It Shouldn’t Be This Hard to Get Our MS Medications

Aubagio, Columns, Lemtrada, Ocrevus, The MS Wire - A Column by Ed Tobias

I got a phone call from my MS One to One nurse, Lynn, today. One to One is the patient support service provided by Sanofi Genzyme for patients on ... Read more

March 8, 2018March 11, 2019

Can Do MS Launches ‘MS Path 2 Care’ to Help Patients Be Equal Partners in Care

Aubagio, News

Can Do MS has launched an MS Path 2 Care initiative that aims to help people affected by MS  be more active partners in their healthcare experience. A national non-profit organization ... Read more

February 27, 2018March 11, 2019

What’s Hot and What’s Not Among MS Therapies?

Aubagio, Columns, The MS Wire - A Column by Ed Tobias

The newest kids on the MS block, disease-modifying therapies (DMT) such as Genentech’s Ocrevus (ocrelizumab) and Sanofi Genzyme’s Lemtrada (alemtuzumab), are attracting a lot of interest these days. But, ... Read more